M2受体自身抗体在围产期心肌病中的初步研究

马桂伶; 乐音; 侯东燕; 张智勇; 张麟

doi:10.13201/j.issn.1001-1439.2021.05.012

M2受体自身抗体在围产期心肌病中的初步研究

- 首都医科大学附属北京朝阳医院心脏中心高血压病研究北京市重点实验室首都医科大学心血管疾病研究所(北京,100020)
基金项目:
国家自然科学基金项目(No:81370340)

详细信息

通讯作者: 张麟,E-mail:zhanglinpeking@aliyun.com

中图分类号: R542.2

收稿日期: 2020-12-09

A preliminary study of autoantibodies against the M2-muscarinic receptor in peripartum cardiomyopathy patients

- Heart Center&Beijing Key Laboratory of Hypertension Disease, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China

More Information

Corresponding author: ZHANG Lin, E-mail: zhanglinpeking@aliyun.com

Received Date: 09 December 2020

摘要

摘要: 目的:评估M2受体自身抗体(anti-M2-R)与围产期心肌病(PPCM)患者预后的相关性。方法:本研究为前瞻性单中心观察性研究。连续入选1998—2018年84例就诊于北京朝阳医院的PPCM患者。ELISA法检测血清anti-M2-R水平,根据检测结果分为anti-M2-R阴性组和阳性组。所有的PPCM患者均给予标准抗心力衰竭(心衰)治疗,专人定期随访,定期监测实验室指标、心脏超声和6分钟步行试验。经过平均5年的随访,比较两组患者临床相关指标和全因死亡率、心血管死亡率、心衰再住院率的差异。结果:80例PPCM患者完成了最终数据分析,其中anti-M2-R阳性组37例,anti-M2-R阴性组43例。两组患者治疗后左心室舒张末期内径、左室射血分数、心功能分级、6分钟步行距离均有明显改善(P<0.01)。其中,anti-M2-R阴性组患者美托洛尔最大耐受剂量更高[(38.4±5.0) mg, 2次/d∶(26.6±4.3) mg, 2次/d,P<0.01],滴定速度更快[(67.0±10.9)d∶(82.8±11.9)d,P<0.01],左室射血分数更高[(62.4±6.7)%∶(57.5±7.4)%,P<0.05]。Anti-M2-R阴性组心衰再住院率显著降低(P<0.05),但两组间全因死亡率和心血管死亡率没有统计学差异。结论:PPCM患者的整体预后相对较好,尤其是anti-M2-R阴性的患者,这可能与自主神经系统的调节有关。anti-M2-R可能参与PPCM的发病,需进一步研究证实并阐明其潜在机制。
- 围产期心肌病 /
- 心力衰竭 /
- M2受体自身抗体 /
- 预后
Abstract: Objective: To evaluate the association of autoantibodies against the M2-muscarinic receptor(anti-M2-R) on prognosis of peripartum cardiomyopathy(PPCM) patients with standard treatment.Methods: This was a single center, prospective, observational study, which began in January 1998 and ended in December 2018. The 84 consecutive patients with newly diagnosed PPCM were enrolled at Beijing Chao-Yang Hospital. Synthetic peptides corresponding to the M2 receptor served as the target antigens in an ELISA experiment. They were used to screen sera of the 84 PPCM patients, who were separated into anti-M2-R-negative or positive group. All the PPCM patients received standard therapy regimens and they were assigned to one of the designated investigators and received follow-up examinations for 5 years after the initiation of the study. Clinical assessment, echocardiography examination and 6-minute walk test were performed regularly. The primary endpoint events were all-cause mortality, cardiovascular mortality, and re-hospitalization for heart failure.Results: The 80 PPCM patients completed the final data analysis, including 37 in the anti-M2-R(+) group and 43 in the anti-M2-R(-) group. Both groups showed improvement in the left ventricular end-diastolic dimensions, the left ventricular ejection fraction, New York Heart Association functional classes and 6-minutes walk distance with standard treatment regimens and follow-up for 5 years(all P<0.01). Anti-M2-R(-) patients had greater tolerance and more rapidly titrated to metoprolol(38.4±5.0 mg bid: 26.6±4.3 mg bid, P<0.01; 67.0±10.9 days: 82.8±11.9 days, P<0.01), and they had better improvement in left ventricular ejection fraction than patients in the anti-M2-R(+) group(62.4±6.7%: 57.5±7.4%, P<0.05). Anti-M2-R(-) patients had a marked decrease of re-hospitalization(P<0.05) but not of all-cause mortality or cardiovascular mortality.Conclusion: PPCM patients have a relatively better prognosis than other patients, especially anti-M2-R(-) patients, which may be related to the regulation of autonomic nervous system. We posit that anti-M2-R may be involved in the pathogenesis of PPCM, which need further study to confirm and clarify its potential mechanism.
- peripartum cardiomyopathy /
- heart failure /
- anti-M2-R /
- prognosis

HTML全文

参考文献(23)

[1]	Honigberg MC,Givertz MM.Peripartum cardiomyopathy[J].BMJ,2019,364:k5287.
[2]	Sliwa K,Hilfiker-Kleiner D,Petrie MC,et al.Current state of knowledge on aetiology,diagnosis,management,and therapy of peripartum cardiomyopathy:a position statement from the Heart Failure Association of the European Society of Cardiology Work Group on peripartum cardiomyopathy[J].Eur J Heart Fail,2010,12(8):767-778.
[3]	车千秋,王琼英,梁宇博,等.围产期心肌病危险因素研究进展[J].临床心血管病杂志,2019,35(11):979-982.
[4]	Ansari AA,Fett JD,Carraway RE,et al.Autoimmune mechanisms as the basis for human peripartum cardiomyopathy[J].Clin Rev Allergy Immunol,2002,23(3):301-324.
[5]	Haberland A,Wallukat G,Schimke I.Aptamer binding and neutralization of b1-adrenoceptor autoantibodies:basic and a vision of its future in cardiomyopathy treatment[J].Trends Cardiovasc Med,2011,21(6):177-182.
[6]	Zhang L,Hu D,Li J,et al.Autoantibodies against the myocardial beta(1)-adrenergic and M2-muscarinic receptors in patients with congestive heart failure[J].Chin Med J(Engl),2002,115(8):1127-1131.
[7]	Miao GB,Liu JC,Liu MB,et al.Autoantibody against beta1-adrenergic receptor and left ventricular remodeling changes in response to metoprolol treatment[J].Eur J Clin Invest,2006,36(9):614-620.
[8]	Du Q,Wu J,Wang H,et al.Perindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptor[J].BMC Cardiovasc Disord,2013,13:94.
[9]	Wang X,Zhang Y,Zhang J,et al.Multiple autoantibodies against cardiovascular receptors as biomarkers in hypertensive heart disease[J].Cardiology,2019,142(1):47-55.
[10]	Sterin-Borda L,Gorelik G,Borda E.Chagasic IgG binding with cardiac muscarinic cholinergic receptors modifies cholinergic-mediated cellular transmembrane signals[J].Clin Immunol Immunopathol,1991,61(3):387-397.
[11]	Liu J,Wang Y,Chen M,et al.The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors[J].PLoS ONE,2013,9(1):e86770.
[12]	赵跃华,孟小敏,李向欣,等.心力衰竭诊断与药物治疗的研究进展[J].临床心血管病杂志,2020,36(4):382-386.
[13]	Fett JD.Long-term maternal outcomes in patients with peripartum cardiomyopathy(PPCM)[J].Am J Obstet Gynecol,2009,201(6):e9;author reply e9-10.
[14]	Harper MA,Meyer RE,Berg CJ.Peripartum cardiomyopathy:population-based birth prevalence and 7-year mortality[J].Obstet Gynecol,2012,120(5):1013-1019.
[15]	McNamara DM,Elkayam U,Alharethi R,et al.Clinical outcomes for peripartum cardiomyopathy in North America:results of the IPAC Study(Investigations of Pregnancy-Associated Cardiomyopathy)[J].J Am Coll Cardiol,2015,66(8):905-914.
[16]	Sliwa K,Mebazaa A,Hilfiker-Kleiner D,et al.Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy(PPCM):EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM[J].Eur J Heart Fail,2017,19(9):1131-1141.
[17]	Ma G,Wang Y,Hou D,et al.Association of autoantibodies against the M2-muscarinic receptor with long-term outcomes in peripartum cardiomyopathy patients:A 5-year prospective study[J].J Cardiol,2019,74(3):251-257.
[18]	Fu LX,Schulze W,Wallukat G,et al.A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits[J].Clin Immunol Immunopathol,1996,78(2):203-207.
[19]	Matsui S,Fu ML,Katsuda S,et al.Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits[J].J Mol Cell Cardiol,1997,29(2):641-655.
[20]	Ribeiro KC,Campelo RP,Rodrigues DDRF,et al.Immunization with plasmids encoding M2 acetylcholine muscarinic receptor epitopes impairs cardiac function in mice and induces autophagy in the myocardium[J].Autoimmunity,2018,51(5):245-257.
[21]	Fernandez SF,Canty Jr JM.Adrenergic and cholinergic plasticity in heart failure[J].Circ Res,2015,116(10):1639-1642.
[22]	Olshansky B,Sabbah HN,Hauptman PJ,et al.Parasympathetic nervous system and heart failure:pathophysiology and potential implications for therapy[J].Circulation,2008,118(8):863-871.
[23]	李清秀,李华,马静.产后急性左心衰竭误诊教训[J].临床心血管病杂志,2020,36(12):1147-1149.